Innovation to Adopt (I2Adopt)

logo I2adopt

Funding which supports commercially viable innovation for implementation, adoption

Aim

Funding to support development of a clinically significant and commercially viable innovation to accelerate commercialization and eventual implementation and adoption of the innovation to impact and benefit healthcare delivery and patient care

Eligibility

The Principal Investigator must hold a primary appointment in and be under the employment of a public healthcare institution or academic medical school in Singapore.

Considerations for project gearing toward clinical adoption:

- Commercial position: Interest to trial for eventual implementation and adoption cross cluster.
- Two or more clusters indicating interest to implement & adopt post-pilot (in Letter of Interest)
- Approved/Registered or close to regulatory approval or registration; ethics submission or approval (as applicable)
- Industry partner’s commitment to pilot and implement

Theme (Screening):

To detect early onset of disease indicators
Enhance proactive screening in homes, primary or community care settings

Funding criteria

Grant applications that emphasise on the following aspects of the project are considered for funding:

Well defined unmet healthcare need
Clear deployment and product development strategy/roadmap
Potential to result in reduced healthcare costs, improved clinical outcome and eventual adoption by the healthcare system.
Proven scientific merit with proof-of-concept data in in vitro and/or in vivo research/laboratory models
Strong intellectual property position will have an advantage

Funding Quantum

Up to $1Mil^

^Quantum reviewed on a Project by Project basis

Funding Duration

12 months, Up to 18 months

Grant call opens

1 November 2022

Anticipated Time Line

	Remarks	Estimated dates
1	Grant Call Opens- submission of Letter of Intent from PHI	1 Nov 2022
2	Grant Call Closes	3 Jan 2023
3	Invite to full proposal	Feb 2023
4	Evaluation	Apr 2023
5	Funding Decision	May 2023

Grant Process

i2A Clinical Innovation amd Adoption Initiative Grant Process

All grant applications are evaluated based on the criteria detailed below.
LOI template can be downloaded here
Only shortlisted applicants will be invited to submit full proposal and pitch to the Evaluation Panel
For further queries on this grant, please contact NHIC at This email address is being protected from spambots. You need JavaScript enabled to view it.

NHIC I2Adopt Evaluation Criteria Considerations

Category	Considerations
Background & data	What is the level of maturity? (evidence to demonstrate the safety and efficacy of the solution) Is the clinical gap and clinical workflow clear?
Uniqueness of technology	How is the product /solution better than current options in the market? What is the market size, competitive landscape, route to market?
Implementation plan & deliverables	Readiness of deployment, has it been deployed or implemented in healthcare system? Is there intention of support to co-develop and/or trial and/or implement cross-cluster from PHIs? Does the proposal include coherent, logical product deployment roadmap? Are clear logical methodologies to overcome potential deployment barriers outlined? Does data from the technology support and de-risk implementation challenges?
Business Considerations	Is there management, stakeholder buy-in and support for adoption? Is there any co-innovation/co-development potential?
Healthcare impact	Is the clinical need elaborated, evidenced clearly? Is there clear validated evidence of advantage of the innovation as compared to others? (through cost-savings, increased value, benefits to healthcare) Is there potential for global commercialization?
Team Composition	Is Project Team experienced in innovation, translation to engage stakeholders for implementation? Is there commitment and adequate support from industry partner?
Budget	Is the budget realistic for the work outlined?

Upcoming I2Adopt Grant Calls

I2Adopt Cycle 2 on Diagnostics and Monitoring: Opens 3 April 2023, closes 2 May 2023
I2Adopt Cycle 3 on Intervention: Opens 4 Aug 2023, closes 4 Sept 2023